On May 18, 2021, following Health Canada authorization of the Pfizer-BioNTech COVID-19 vaccine for 12 to 15 years of age, NACI recommended the use of the vaccine in adolescents (Strong NACI Recommendation) based on a review of available evidence including additional clinical trial results in the adolescent population. Since then, NACI has reassessed its recommendations on the use of mRNA COVID-19 vaccines in adolescents, considering additional evidence including clinical data on the efficacy, safety, and immunogenicity of the Moderna COVID-19 vaccine in adolescents as well as post-market safety and effectiveness reports on both mRNA COVID-19 vaccines.

Recommendation Americas Canada adolescents mRNA vaccines COVID-19